- Dr. Andrea Richardson and colleagues have identified a genetic marker that may predict which aggressive "triple negative" breast cancers and certain ovarian cancers will likely respond to platinum-based chemotherapies.
Tags: BreastCancer, Genomics, OvarianCancer, GynecologicCancers
- Breast cancer surgeons have been having an ongoing discussion on how much tissue to breast tissue to remove when removing a tumor. Dr. Mehra Golshan said that with ductal carcinoma in situ (DCIS), a very treatable, early stage cancer, smaller margins are acceptable and appropriate.
Tags: BreastCancer, Surgery
- Epigenetics was the subject of a particularly interesting session, held on April 1st, at a meeting of the American Association for Cancer Research in Chicago. James Bradner, MD, described how his group has shown that a substance known as JQ1, which inhibits an epigenetic regulator called BRD4, blocks the activity of a gene by the name of Myc.
- Dr. Deborah Schrag reported in the Journal of the American Medical Association that non-small cell lung cancer patients 65 years of age and older did not receive any survival benefit when Avastin was added to their standard chemotherapy. This finding counters an earlier study.
- Research has shown that a genetic abnormality behind one illness may also cause other disorders. These shared genetic links may put a person at greater risk for developing related diseases. Dr. Marc Vidal says that because of this interconnectivity, drug companies need to be careful in developing drugs as the treatment for one disease could cause severe side effects.
- Fifteen Dana-Farber nurses were nominated by patients for inclusion in the Boston Globe's Salute to Nurses section, including Judy Dynan, RN, Kerri Beliveau, RN, Debra LaFrank, RN, Annette Werger, RN.
- Dr. Glenn Dranoff talks about the new era of immune therapies being recognized as an important component of cancer treatment.
- Patriots players Devin McCourty and Julian Edelman visited patients and signed autographs at the Kraft Family Blood Donor Center at Dana-Farber as part of the Patriots Charitable Foundation’s Celebrate Volunteerism campaign.
Tags: NewEnglandPatriots, BloodDonation
- A study led by Dr. Mary Ellen Taplin that looked at small group of men with prostate cancer showed that treatment with Zytiga eliminated or greatly reduced the size of prostate tumors in one-third of patients treated for six months before surgery.
- Dr. Ann Partridge discusses new efforts for improved survivorship care. Catherine Fitch, a former Dana-Farber patient, provides insight into the challenges she has faced in the 36 years since surviving Hodgkin's lymphoma.
Tags: Survivorship, Lymphoma
Showing 21-30 of 216 items